Methods and Materials
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Interfractional variation in position of the uterus during radical radiotherapy for cervical cancer.Radiother Oncol. 2004; 71: 73-79
- Inter- and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: A cinematic-MRI point-of-interest study.Int J Radiat Oncol Biol Phys. 2008; 70: 1507-1515
- Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: Radiobiologic modeling and correlation with tumor hypoxia.Int J Radiat Oncol Biol Phys. 2008; 70: 126-133
- Translating response during therapy into ultimate treatment outcome: A personalized 4-dimensional MRI tumor volumetric regression approach in cervix cancer.Int J Radiat Oncol Biol Phys. 2010; 76: 719-727
- Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression.Int J Radiat Oncol Biol Phys. 2006; 64: 189-196
- Pelvic radiotherapy for cancer of the cervix: Is what you plan actually what you deliver?.Int J Radiat Oncol Biol Phys. 2009; 74: 304-312
- Motion, and deformation of the target volumes during IMRT for cervical cancer: What margins do we need?.Radiother Oncol. 2008; 88: 233-240
- Online MRI guidance for healthy tissue sparing in patients with cervical cancer: An IMRT planning study.Radiother Oncol. 2008; 88: 241-249
- Automated weekly replanning for intensity-modulated radiotherapy of cervix cancer.Int J Radiat Oncol Biol Phys. 2010; 78: 350-358
- Hybrid adaptive radiotherapy with on-line MRI in cervix cancer IMRT.Radiother Oncol. 2014; 110: 323-328
- A margin-of-the-day online adaptive intensity-modulated radiotherapy strategy for cervical cancer provides superior treatment accuracy compared to clinically recommended margins: A dosimetric evaluation.Acta Oncol. 2013; 52: 1430-1436
- Mapping pelvic lymph nodes: Guidelines for delineation in intensity-modulated radiotherapy.Int J Radiat Oncol Biol Phys. 2005; 63: 1604-1612
- Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer.Int J Radiat Oncol Biol Phys. 2011; 79: 348-355
- A general software framework for investigations in radiation therapy planning.Med Phys. 2006; 33: 2273
- Accuracy of finite element model-based multi-organ deformable image registration.Med Phys. 2005; 32: 1647-1659
- Development of multiorgan finite element-based prostate deformation model enabling registration of endorectal coil magnetic resonance imaging for radiotherapy planning.Int J Radiat Oncol Biol Phys. 2007; 68: 1522-1528
- Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies.Int J Radiat Oncol Biol Phys. 2002; 54: 1388-1396
- Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies.Gynecol Oncol. 2001; 82: 456-463
- Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy.Int J Radiat Oncol Biol Phys. 2003; 56: 1354-1360
- Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation.Int J Radiat Oncol Biol Phys. 2001; 51: 261-266
- Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies.Int J Radiat Oncol Biol Phys. 2000; 48: 1613-1621
This work was supported by RaySearch Laboratories AB , the Canadian Institutes of Health Research Strategic Fellowship in the Excellence in Radiation Research for the 21st Century Program, the Giovanni and Concetta Guglietti Family Trust , the National Sciences and Engineering Research Council of Canada , and the Ontario Consortium for Adaptive Interventions in Radiation Oncology .
Drs Lim and Stewart contributed equally to this work and share first authorship.
Conflict of interest: Anna Lundin, Henrik Rehbinder, and Johan Löf are employees and shareholders of RaySearch Laboratories AB. David Jaffray, Joanne Moseley, and Kristy Brock have a commercial licensing agreement with RaySearch Laboratories AB. The authors report no other conflicts of interest.